Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator.

[1]  S. Yusuf,et al.  Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.

[2]  S. Kernis,et al.  Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? , 2004, Journal of the American College of Cardiology.

[3]  K. Eagle,et al.  Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes , 2004, Circulation.

[4]  P. Serruys,et al.  Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention , 2002 .

[5]  R. Erbel,et al.  Preprocedural Statin Medication Reduces the Extent of Periprocedural Non–Q-Wave Myocardial Infarction , 2002, Circulation.

[6]  Deepak L. Bhatt,et al.  Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. , 2002, Journal of the American College of Cardiology.

[7]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[8]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[9]  G. Fonarow,et al.  Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3 , 2001, Circulation.

[10]  W. Rogers,et al.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. , 2000, Journal of the American College of Cardiology.

[11]  P. Grande,et al.  The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). , 2000, Journal of the American College of Cardiology.

[12]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[13]  D. Holmes,et al.  Medical Therapy after Successful Percutaneous Coronary Revascularization , 1999, Annals of Internal Medicine.

[14]  R. Dinsmore,et al.  Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. , 1999, The American journal of cardiology.

[15]  A. Castaigne,et al.  Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. , 1997, Journal of the American College of Cardiology.

[16]  W. O’Neill,et al.  Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.